Payment overview · 2025
General Payments
$317.81
12 reported records · 6 companies
Healthcare provider profile · identity verified
Abigail Jane Wilhite, MD
Allopathic & Osteopathic Physicians|Family Medicine · MURFREESBORO, AR · NPI 1073076550
Verified facts
What the public records show
CMS Open Payments records show Abigail Jane Wilhite, MD received $317.81 in general payments during 2025 across 12 reported records.
Eisai Inc. accounted for 32.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Eisai Inc. | Unresolved — no canonical attribution shown | $102.09 | 32.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $96.93 | 30.5% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $53.11 | 16.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.53 | 10.6% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $17.27 | 5.4% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.88 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $317.81 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $102.09 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $96.93 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $70.38 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $33.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
117 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 376 | 84 |
| Gabapentin | Gabapentin | 316 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 306 | 65 |
| Furosemide | Furosemide | 254 | 63 |
| Eliquis | Apixaban | 239 | 28 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 53 |
| Potassium Chloride | Potassium Chloride | 231 | 44 |
| Trazodone Hcl | Trazodone Hcl | 214 | 48 |
| Divalproex Sodium | Divalproex Sodium | 213 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 53 |
| Citalopram Hbr | Citalopram Hydrobromide | 184 | 30 |
| Mirtazapine | Mirtazapine | 182 | 30 |
| Omeprazole | Omeprazole | 180 | 50 |
| Lisinopril | Lisinopril | 172 | 48 |
| Donepezil Hcl | Donepezil Hcl | 163 | 26 |
| Losartan Potassium | Losartan Potassium | 157 | 40 |
| Carvedilol | Carvedilol | 145 | 30 |
| Azithromycin | Azithromycin | 132 | 106 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 130 | 32 |
| Lorazepam | Lorazepam | 120 | 24 |
| Meloxicam | Meloxicam | 120 | 34 |
| Jardiance | Empagliflozin | 117 | 12 |
| Tamsulosin Hcl | Tamsulosin Hcl | 106 | 31 |
| Memantine Hcl | Memantine Hcl | 105 | 18 |
| Spironolactone | Spironolactone | 102 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 27 |
| Januvia | Sitagliptin Phosphate | 100 | 12 |
| Metformin Hcl | Metformin Hcl | 99 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 99 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 42 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 17 |
| Simvastatin | Simvastatin | 90 | 20 |
| Sertraline Hcl | Sertraline Hcl | 89 | 19 |
| Alprazolam | Alprazolam | 86 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 86 | 19 |
| Mounjaro | Tirzepatide | 85 | 12 |
| Ozempic | Semaglutide | 85 | 11 |
| Buspirone Hcl | Buspirone Hcl | 81 | 15 |
| Famotidine | Famotidine | 81 | 15 |
| Farxiga | Dapagliflozin Propanediol | 75 | suppressed |
| Methocarbamol | Methocarbamol | 74 | 20 |
| Entresto | Sacubitril/Valsartan | 70 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 70 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 69 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 20 |
| Prednisone | Prednisone | 65 | 47 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 61 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 60 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 42 |
| Allopurinol | Allopurinol | 58 | 16 |
| Cefdinir | Cefdinir | 57 | 52 |
| Tramadol Hcl | Tramadol Hcl | 56 | 19 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 17 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Nystatin | Nystatin | 54 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 18 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 32 |
| Metformin Hcl Er | Metformin Hcl | 50 | 13 |
| Tresiba | Insulin Degludec | 50 | suppressed |
| Clonazepam | Clonazepam | 49 | suppressed |
| Ondansetron Odt | Ondansetron | 49 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 36 |
| Montelukast Sodium | Montelukast Sodium | 47 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 14 |
| Trulicity | Dulaglutide | 42 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Fluconazole | Fluconazole | 40 | 27 |
| Sucralfate | Sucralfate | 40 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 39 | 19 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 38 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 33 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Brilinta | Ticagrelor | 27 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Levetiracetam | Levetiracetam | 25 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 15 |
| Cephalexin | Cephalexin | 23 | 18 |
| Fentanyl | Fentanyl | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 22 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 21 | 16 |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 21 | suppressed |
| Movantik | Naloxegol Oxalate | 21 | suppressed |
| Nyamyc | Nystatin | 21 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 20 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 19 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Myrbetriq | Mirabegron | 18 | suppressed |
| Olanzapine Odt | Olanzapine | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Dexamethasone Sodium Phosphate | Dexamethasone Sodium Phosphate | 17 | 15 |
| Humalog | Insulin Lispro | 17 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 16 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 16 | 14 |
| Promethazine Hcl | Promethazine Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Levemir | Insulin Detemir | 14 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 14 | 11 |
| Novolin R | Insulin Regular, Human | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Lubiprostone | Lubiprostone | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $317.81 · 12 records | Eisai Inc. | CAPLYTA, Lenvima, MOUNJARO, QULIPTA, REXULTI, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error